The AIM Attraction


Contrary to popular belief, both institutional and private investors do have huge pots of cash for the right companies looking to IPO. 

In this article, Mark Fahy and Marcus Stuttard of the London Stock Exchange talk to Criticaleye about AIM’s enduring strength through the economic downturn and why it can be the perfect home for growth businesses needing an injection of capital.

The article also includes Community Comment from AIM veterans Clive Ansell, Robert Drummond and Faisal Rahmatallah

Share this with your Community


Contributors
Clive Ansell
Non-Executive Director
Eckoh plc
Marcus Stuttard
Head of AIM and UK Primary Markets
London Stock Exchange Group
Mark Fahy
Former Head of UK Small & Mid-Cap Companies

Robert Drummond
Chairman & Non-executive Director
North East Finance


Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Inspiring Leaders Podcast: Wh...

Matthew Blagg, CEO for Criticaleye, joins Marketing and Communications Director Julia Brook for the first Inspiring Leaders podcast for 2026. They take a look at some of the lessons for leaders last year, and examin...

Inspiring Leaders Podcast: Na...

Dave Wilson, Chair of LBG Media (LADbible) and Knights plc, joins Criticaleye’s Senior Editor Jacob Ambrose Willson to explore how Boards and executive teams can successfully navigate today’s capital markets...

Click here to download this insight
2026 Enterprise Software Tech...

In this report, Criticaleye Partner AlixPartners suggest that 2026 will likely mark a structural turning point for enterprise software, as AI reshapes not only how software is built, but how it is priced,...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 310




Worldpay Rolls-Royce Aldermore Group Salesforce FTSE Women Leaders Review Palo Alto Networks London Stock Exchange Group Legal & General IBM Consulting NatWest Group Concentrix Accenture Workday Hitachi Solutions E.ON UK AlixPartners Lightsource bp GlaxoSmithKline plc Drax Group plc Eightfold AI British Land Google NATS